1. Scrip
  2. >>New Products

Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti

First Multiple Myeloma Patient Could Be Infused In Six Weeks

 
• By Mandy Jackson

Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage. 

Red balloon mid air amongst wooden square cubes
A phased launch will allow for careful certification of treatment centers • Source: Alamy

Janssen Pharmaceutical Cos. and Legend Biotech Corp. plan a phased launch of their newly approved autologous chimeric antigen receptor T-cell (CAR-T) multiple myeloma therapy Carvykti (ciltacabtagene autoleucel), which targets B-cell maturation antigen (BCMA) on myeloma cells, to make sure treatments centers are ready to properly administer the complex product.

Johnson & Johnson’s Janssen subsidiary and Legend will launch Carvykti at a list price of $465,000 for the one-time treatment, coming in more than $45,000 above the launch price for the first-to-market BCMA-targeting CAR-T therapy Abecma (idecabtagene vicleucel) from Bristol Myers Squibb Company and the bluebird bio spin-out 2seventy Bio, Inc., approved 11 months ago in the US

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

Pipeline Watch: Five Approvals And One Phase III Readout

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Seals SpringWorks Buy

 
• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

More from Scrip

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.